Novartis Ag (NVS) Other Non Operating Income (2009 - 2026)
Novartis Ag recorded quarterly Other Non Operating Income of -$50.0 million in Q1 2026, up 45.65% quarter-over-quarter from -$92.0 million in Q4 2025, and down 394.12% year-over-year from $17.0 million in Q1 2025.
Novartis Ag's Other Non Operating Income history runs 18 years deep, the most recent figure standing at -$50.0 million for Q1 2026.
- In Q1 2026, Other Non Operating Income fell 394.12% year-over-year to -$50.0 million; the TTM figure through Mar 2026 stood at -$203.0 million (down 234.44% YoY), while the FY2025 annual figure was -$136.0 million, down 197.14% from the prior year.
- Other Non Operating Income came in at -$50.0 million for Q1 2026 at Novartis Ag, up from -$92.0 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $104.0 million in Q1 2023 to a low of -$92.0 million in Q4 2025.
- A 5-year average of $12.2 million and a median of $17.0 million in 2025 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income jumped 431.25% in 2023 and sank 394.12% in 2026, its largest moves.
- Novartis Ag's Other Non Operating Income stood at $24.0 million in 2022, then fell by 25.0% to $18.0 million in 2023, then jumped by 83.33% to $33.0 million in 2024, then sank by 378.79% to -$92.0 million in 2025, then jumped by 45.65% to -$50.0 million in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$50.0 million, -$92.0 million, and -$20.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.00 Mn |
| Dec 31, 2025 | -92.00 Mn |
| Sep 30, 2025 | -20.00 Mn |
| Jun 30, 2025 | -41.00 Mn |
| Mar 31, 2025 | 17.00 Mn |
| Dec 31, 2024 | 33.00 Mn |
| Sep 30, 2024 | 26.00 Mn |
| Jun 30, 2024 | 75.00 Mn |
| Mar 31, 2024 | 6.00 Mn |
| Dec 31, 2023 | 18.00 Mn |
| Sep 30, 2023 | 15.00 Mn |
| Jun 30, 2023 | 85.00 Mn |
| Mar 31, 2023 | 104.00 Mn |
| Dec 31, 2022 | 24.00 Mn |
| Sep 30, 2022 | -28.00 Mn |
| Jun 30, 2022 | 16.00 Mn |
| Mar 31, 2022 | 20.00 Mn |
| Dec 31, 2021 | -26.00 Mn |
| Sep 30, 2021 | -24.00 Mn |
| Jun 30, 2021 | -30.00 Mn |
| Mar 31, 2021 | -19.00 Mn |
| Dec 31, 2020 | -25.00 Mn |
| Sep 30, 2020 | -19.00 Mn |
| Jun 30, 2020 | -34.00 Mn |
| Mar 31, 2020 | -7.00 Mn |
| Dec 31, 2019 | -11.00 Mn |
| Sep 30, 2019 | 12.00 Mn |
| Mar 31, 2019 | 44.00 Mn |
| Dec 31, 2018 | 78.00 Mn |
| Sep 30, 2018 | 28.00 Mn |
| Jun 30, 2018 | 45.00 Mn |
| Mar 31, 2018 | 35.00 Mn |
| Dec 31, 2017 | 23.00 Mn |
| Sep 30, 2017 | 14.00 Mn |
| Jun 30, 2017 | 12.00 Mn |
| Mar 31, 2017 | -10.00 Mn |
| Dec 31, 2016 | -365.00 Mn |
| Sep 30, 2016 | -38.00 Mn |
| Jun 30, 2016 | -3.00 Mn |
| Mar 31, 2016 | -41.00 Mn |
| Dec 31, 2015 | -398.00 Mn |
| Sep 30, 2015 | -31.00 Mn |
| Jun 30, 2015 | -82.00 |
| Mar 31, 2015 | 57.00 |
| Dec 31, 2014 | 13.00 |
| Sep 30, 2014 | 37.00 |
| Jun 30, 2014 | -56.00 |
| Mar 31, 2014 | -25.00 |
| Dec 31, 2013 | -42.00 |
| Sep 30, 2013 | -62.00 |
| Jun 30, 2013 | 5.00 |
| Mar 31, 2013 | 7.00 |
| Sep 30, 2012 | -70.00 |
| Jun 30, 2012 | 34.00 |
| Mar 31, 2012 | -41.00 |
| Dec 31, 2011 | -12.00 |
| Sep 30, 2011 | 4.00 |
| Jun 30, 2011 | -16.00 |
| Mar 31, 2011 | 22.00 |
| Dec 31, 2010 | -26.00 |
| Sep 30, 2009 | -323.00 |
| Jun 30, 2009 | -220.00 |
| Mar 31, 2009 | -74.00 |